---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-23-023068"
form_type: "8-K"
ticker: "ERNA"
cik: "0000748592"
company_name: "Ernexa Therapeutics Inc."
filed_at: "2023-05-05T23:59:59+00:00"
generated_at: "2026-06-15T18:39:42.291107+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Eterna Therapeutics appoints Sandra Gurrola as PFO; CFO Jackson resigns with $207,500 severance

## Summary
- Andrew Jackson resigned as CFO effective May 4, 2023; receives $207,500 salary continuation for 6 months plus COBRA premiums.
- Sandra Gurrola appointed as principal financial officer effective May 5, 2023; she was previously VP Finance.
- Jackson forfeited 33,239 unvested stock options granted June 3, 2022.
- Separation agreement includes general release, cooperation, and confidentiality provisions.

## SEC filing metadata
- accession: 0001140361-23-023068
- form_type: 8-K
- ticker: ERNA
- cik: 0000748592
- company_name: Ernexa Therapeutics Inc.
- filed_at: 2023-05-05T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/748592/000114036123023068/0001140361-23-023068-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/748592/000114036123023068/brhc20052521_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-23-023068
- JSON: https://secwatch.observer/filing/0001140361-23-023068.json
- Plain text: https://secwatch.observer/filing/0001140361-23-023068.txt

## Key facts
- Executive change
  Andrew Jackson resigned as Chief Financial Officer at Ernexa Therapeutics Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Mr. Jackson resigned from his position as Chief Financial Officer (principal financial officer) and as an officer, director, manager or employee of the Company’s subsidiaries.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123023068/0001140361-23-023068-index.htm
- Executive change
  Sandra Gurrola was appointed as principal financial officer at Ernexa Therapeutics Inc..
  - Action: appointed
  - Role: principal financial officer
  source text: appointed Sandra Gurrola, the Company’s current Vice President, Finance (and principal accounting officer), as the Company’s principal financial officer, which appointment became effective on May 5, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/748592/000114036123023068/0001140361-23-023068-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.